Recombined humanized endostatin (Endostar) intravenous infusion in the treatment of refractory nasopharyngeal carcinoma: Three case reports
Rationale:
Refractory nasopharyngeal carcinoma is challenging to treat and at present there is no standard treatment or any good choice.
Patient concerns:
Although the three patients in our case reports had already underwent multiple treatments before, they still suffered from disease recurrence of nasopharyngeal carcinoma.
Diagnosis:
They were diagnosed as refractory nasopharyngeal carcinoma.
Interventions:
A continuous infusion of Endostar, an antiangiogenic agent, combined with chemotherapy and radiation therapy was given to treat the patients.
Outcomes:
Patients showed complete or partial response to the combined therapy as evidenced by regression of tumors and decrease in plasma Epstein–Barr virus (EBV) DNA load.
Lessons:
Continuous infusions of Endostar in combination with chemotherapy and/or radiation therapy showed promising efficacy and safety. The combination therapy indicates a new approach to treat refractory nasopharyngeal carcinoma.
Source: Medicine - Category: Internal Medicine Tags: Research Article: Clinical Case Report Source Type: research
More News: Cancer & Oncology | Carcinoma | Chemotherapy | Internal Medicine | Lessons | Nasopharyngeal Cancer | Radiation Therapy